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ABSTRACT 
Purpose Dry powder vaccine delivery via the pulmonary route has gained significant attention as an 
alternate route to parenteral delivery. In this study, we investigated bovine serum albumin (BSA) 
adsorbed poly(glycerol adipate-co-ω-pentadecalactone), PGA-co-PDL polymeric nanoparticles (NPs) 
within L-leucine (L- leu) microcarriers for dry powder inhalation. 
Methods NPs were prepared by oil-in-water single emulsion-solvent evaporation and particle size 
optimised using Taguchi’s design of experiment. BSA was adsorbed onto NPs at different ratios at room 
temperature. The NPs were spray-dried in aque- ous suspension of L-leu (1:1.5) using a Büchi-290 mini-
spray dryer. The resultant nanocomposite microparticles (NCMPs) were characterised for toxicity 
(MTTassay), aerosolization (Next Generation Impactor), in vitro release study and BSA was 
characterized using SDS-PAGE and CD respectively. 
Results NPs of size 128.50±6.57 nm, PDI 0.07±0.03 suitable for targeting lung dendritic cells were 
produced. BSA adsorption for 1 h resulted in 10.23±1.87 μg of protein per mg of NPs. Spray-drying with 
L-leu resulted in NCMPs with 42.35±3.17%yield. In vitro release study at 37°C showed an initial burst 
release of 30.15±2.33% with 95.15±1.08% over 48 h. Aerosolization studies indicated fine particle 
fraction (FPF%) dae<4.46 μm as 76.95 ± 5.61% and mass median aerodynamic diameter (MMAD) of 
1.21 ± 0.67 μm. The cell viability was 87.01± 14.11% (A549 cell line) and 106.04±21.14% (16HBE14o-
cell line) with L-leu based NCMPs at 1.25 mg/ml concentration after 24 h treatment. The SDS-PAGE 
and CD confirmed the primary and secondary structure of the released BSA. 
Conclusions The results suggest that PGA-co-PDL/L-leuNCMPs may be a promising carrier for 
pulmonary vaccine delivery due to excellent BSA adsorption and aerosolization behaviour. 
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ABBREVIATIONS 
APCs Antigen presenting cells 
BSA Bovine serum albumin 
DCs Dendritic cells 
DoE Design of experiment 
LN Lymph node 
NPs Nanoparticles 
NCMPs    Nanocomposite microparticles 
PGA-co-PDL Poly(glycerol   adipate-co-ω-pentadecalactone)  
PLA Polylactide or poly-L-lactic acid 
PLGA Poly lactic-co-glycolic-acid 
PVA Polyvinyl alcohol 
SD Spray-drying 
 
 
 
 
 
INTRODUCTION 
Vaccination refers to induction of an immune response using antigens coupled with adjuvants for 
generating a protective immunity against plausible future infections (1,2). Traditional vaccines are 
often administered via the parenteral route requiring infrastructure such as cold-chain, sterilized water 
for reconstitution of dry powder vaccines and trained medical personnel. Lack of these facilities in 
low and middle income countries (LMICs) is leading to many eligible children and adults not getting 
vaccinated (3). Moreover, the majority of the potential vaccines in development employ purified subunits or 
recombinant proteins that are often poorly immunogenic thus needing adjuvants and effective delivery 
systems to generate an optimal immune response (1,2). To address these issues, particulate delivery 
systems and non-invasive routes of delivery are being investigated. The pulmonary route has gained 
significant attention for delivery of vaccines as it is one of the main entry portals for pathogens, and can 
address some of the challenges such as invasiveness, cold-chain requirement, and stability of the antigen 
by delivering the antigen as a dry powder (3). 
Biodegradable polymeric nanoparticles (NPs) have gained significant attention and are largely being 
explored as delivery vehicles for delivery of peptides, proteins, antigens, DNA etc. (3–5). These polymers 
offer controlled or sustained drug release, biocompatibility with surrounding cells and tissues, degrade into 
low molecular weight non-toxic products and act as adjuvants helping in generating cellular and humoral 
immune responses (1,3,6). In this current investigation we aim to use poly(glycerol adipate-co-ω-
pentadecalactone), PGA-co-PDL, a biodegradable polyester polymer, that has extensively been studied 
by our group for delivery of both small molecule and model drugs (dexamethasone phosphate, ibuprofen, 
sodium fluorescein), and large molecule drugs (α-chymotrypsin, DNase I) (7–10). 
In these biodegradable polymeric nanoparticulate formu- lations, the vaccine antigens (i.e. proteins, 
peptides etc.) are either adsorbed onto the surface or encapsulated within the particles (3). 
Encapsulated antigens are protected by polymeric NPs and their release can be modified by tailoring 
the properties of the polymers. Adsorbed antigen, however, offers enhanced stability and activity over 
the encapsulated antigen by avoiding contact with organic solvents employed during particle 
preparation steps (11–13). 
Recent strategies for effective vaccine delivery have been to target the dendritic cells (DCs), the true 
professional antigen presenting cells (APCs) (14). DCs have the exceptional ability to internalize, and 
in lymph nodes (LNs) they process and present antigens through major histocompatibility complex 
(MHC) class I and II pathways thereby activating naïve T- cells resulting in induction of a strong 
immune response (3,14,15). A study conducted by Manolova et al. indicates the importance of particle 
size in determining the uptake by DCs, where it was shown that upon intracutaneous injection of 
polystyrene beads of varying sizes, large particles (500– 2,000 nm) associated with DCs from the 
site of injection whereas small particles (20–200 nm) drained freely to the LNs and were present in 
LN resident DCs (15). In addition, Kim et al. have shown that uptake of 200 nm sized NPs by bone 
marrow DCs to be more than that of 30 nm sized NPs (16). Furthermore, Foged et al. has shown that 
particle size of 500 nm or below were preferred and have shown fast and efficient up take by human 
DCs derived from blood (17). The above literature suggests that smaller particles of 200 to 500 nm 
could effectively be up taken by DCs and thus generates a stronger immune response compared to 
vaccine alone. However, these studies cannot be directly compared to lung DCs but owing to the lack 
of information on the effect of NP size on uptake by lung DCs the same can be assumed. 
In this study, the Taguchi L18 orthogonal array design of experiment (DoE) was used to optimize the 
formulation parameters to achieve NPs (~150 nm) for targeting the lung DCs. The literature suggests that 
factors such as molecular weight (MW) of the polymer, organic solvent, aqueous phase, sonication time and 
stirrer speed have an influence on the size of the resultant NPs (18–20) and these were evaluated using 
the experimental design. As a dry powder, the nanosized particles cannot be directly used for inhalation 
as their size is too small and it is expected that majority of the inhaled dose will be exhaled depositing 
very minimal doses in the lung (21). Thus, these NPs are formulated into nanocomposite microparticles 
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(NCMPs) using additives such as lactose (22), L-leucine (L-leu) (22,23), trehalose (24), mannitol (24) 
by various manufacturing techniques such as freeze drying, spray drying (SD), spray-freeze drying or 
super- critical fluid technologies (3,25). The NCMPs in the size range of 1 to 5 μm in diameter are 
reported to be deposited in the respirable airways and periphery of the lung (26). The additives used to 
form NCMPs dissolve upon encountering the respiratory environment thereby releasing the NPs (27). 
In this project, we aim to produce PGA-co-PDL NPs of optimum size to be effectively taken up by 
the DCs, surface adsorb a model protein, bovine serum albumin (BSA) and formulate into 
nanocomposite microparticles (NCMPs) using L-leu as a carrier for delivery via dry powder inhalation. 
 
 
MATERIALS AND METHODS 
 
Materials 
Dichloromethane (DCM) was purchased from BDH, laboratory supplies, UK. Novozyme 435 (a lipase from 
Candida antartica immobilized on a microporous acrylic resin) was purchased from Biocatalytics, USA. 
Acetonitrile (HPLC grade), albumin tagged with fluorescein isothiocyanate (FITC-BSA), bovine serum 
al- bumin (BSA, MW 67 KDa), phosphate buffered saline (PBS, pH 7.4) tablets, poly(vinyl alcohol) 
(PVA, MW 9–10 KDa, 80%),  trifluoroacetic  acid  (TFA,  HPLC  grade),  RPMI-1640 medium with L-
glutamine and NaHCO3, thiazoly blue tetrazo- lium bromide (MTT), tween 80® and ω-pentadecalactone 
were obtained from Sigma-Aldrich, UK. L-leucine (L-leu) was purchased from BioUltra, Sigma, UK. 
Seventy-five cm2/tissue ulture flasks with vented cap, 96-well flat bottom plates, ace- tone, antibiotic/ 
antimycotic solution (100X), dimethyl sulfoxide (DMSO) were purchased from Fisher Scientific, UK. 
Divinyladipate was obtained from Fluorochem, UK. Fetal calf serum (FCS) heat inactivated was purchased 
from Biosera UK. poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL), MW of 14.7, 24.0 
KDa was synthesized in our laboratory at LJMU and micro BCA™ protein assay kit was purchased from 
Thermo Scientific, UK. A549 cell line was purchased from ATCC. 16HBE14o- cells were obtained 
from Dr Dieter Gruenert from the California Pacific Medical Center, University of California San 
Francisco, USA. 
 
Polymer Synthesis 
The PGA-co-PDL polymer of MW of 14.7, 24.0 KDa was synthesized in our laboratory via enzyme 
catalyzed co- polymerization of three monomers as described by Thompson et al. (28). The synthesized linear 
polyester was characterized by gel permeation chromatography, GPC (Viscotek TDA Model 300 using OmniSEC3 
operating software), pre-calibrated with poly- styrene standards (polystyrene standards kit, Supelco, USA), and 1H-NMR 
spectroscopy (Bruker AVANCE 300 MHz, Inverse probe with B-ACS 60, Auto sampler with gradient chemming) 
as described by Thompson et al. (28). 
 
Preparation of Nanoparticles 
PGA-co-PDL NPs were fabricated using a modified oil-in- water (o/w) single emulsion solvent 
evaporation method (29). Briefly, 200 mg PGA-co-PDL polymer (MW 14.7 KDa) (and Nile Red, NR 
0.5 mg for characterization of protein adsorp- tion onto the surface of PGA-co-PDL via confocal 
microscopy) was dissolved in 2 ml DCM and probe sonicated (20 μm amplitude) upon addition to 5 
ml of 10%w/v poly(vinyl alcohol) (PVA) (1st aqueous solution) for 2 min to obtain an emulsion. 
This whole process was performed using ice. This was immediately added drop wise to 20 ml of 2nd 
aqueous solution (0.75%w/v PVA) under magnetic stirring at a speed of 500 RPM. The whole mixture 
 
 
 
was left stirring at room temperature for 3 h to facilitate the evaporation of DCM. The particle size, 
PDI and zeta-potential were then characterised as mentioned in “Nanoparticle Characterization” 
Section. The NP suspensions were collected by centrifugation (78,000 g, 40 min, 4°C) and 
surface adsorbed with protein as indicated in “Protein Adsorption” Section. 
 
Taguchi Design of Experiment (DoE) 
In order to evaluate the influence of formulation parameters and minimize the number of  experiments, 
Taguchi  DoE being appropriate to  study large number of factors, was employed  through  Minitab®   
16  Statistical  Software.  Seven factors, namely, polymer MW, organic solvent, internal aqueous phase 
concentration and volume, sonication time, stirrer speed and external aqueous phase concentration were 
evaluated by constructing and using L18 orthogonal array design with 1 factor, MW, at 2 levels and 
remaining 6 factors at 3 levels (Table I). 
The design was applied to identify the significant factors that would affect the size of PGA-co-
PDL NPs. Optimum conditions were indicated by high signal-to-noise (S/N) ratios, where signal factor 
(S) is the outcome, the particle size, and noise factors (N) are parameters such as humidity, tempera- 
ture, experience of the experimenter etc. A greater S/N ratio corresponds to minimum variance of the 
outcome, the particle size i.e. a better performance. In other words, the experimental parameter having the 
least variability is the optimum condition (30). The optimization of size was carried out using the 
Taguchi’s ‘smaller-is-better’ criterion i.e. to get the outcome, the particle size, to an ideal target of 
zero or as small as possible.  
Table I Taguchi’s Experimental Design L18 for Producing PGA-co-PDL Nanoparticles 
 
 
 
 
 
 
 
 
 
 
 
Protein Adsorption 
NP suspension (equivalent to 10 mg i.e. 1.25 ml of suspension) was centrifuged (78,000 g, 40 min, 4°C) 
and the resultant pellet was resuspended in vials containing 4 ml of BSA (or FITC-BSA for 
characterization of protein adsorption onto the surface of PGA-co-PDL via confocal microscopy), for 1 
h, at different ratios of 100: 4, 100: 10 and 100: 20 (NP: BSA) corresponding to 100, 250 and 500 
μg/ml BSA concentrations, respectively. The resulting suspension (for 100: 20) was left rotating for 
30 min, 1, 2 and 24 h at 20 RPM on a HulaMixer™ Sample Mixer (Life Technologies, Invitrogen, 
UK). After respective time points, the protein adsorbed NP suspensions were centrifuged and the 
supernatant analysed for protein content using micro  BCA protein  assay kit.  The amount of BSA 
adsorbed per milligram of NPs (n=3) was calculated using Eq. 1: 
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Adsorption (µg per mg NPs) 
 
 
 
The particle size and PDI were then characterised as mentioned in “Nanoparticle 
Characterization” Section. 
 
Nanoparticle Characterization 
 
Particle size, poly dispersity index (PDI, a number between 0 and 1 describing the homogeneity of the 
sample) and zeta- potential were measured by laser diffraction using a laser particle size analyser 
(Zetasizer Nano ZS, Malvern Instru- ments Ltd, UK). For NPs suspension, an aliquot of 100 μl was 
diluted with 5 ml of deionized water and for NP suspensions with and without BSA adsorption, 2 mg of 
NPs were resuspended in 5 mL of deionized water, loaded into a cuvette and the measurements were 
recorded at 25°C (n=3). 
 
Nanocomposite  Microparticles 
Spray-drying was employed to incorporate the NPs into nano-composite microparticles (NCMPs) using 
L-leu as a carrier, and at nanoparticles-to-carrier ratio of 1:1.5w/w. Blank NPs, BSA-loaded NPs or 
FITC-BSA-loaded NR NPs were dispersed in 20 ml water with L-leu dissolved and spray-dried 
using a Büchi B-290 mini spray-dryer (Büchi Labortechnik, Flawil, Switzerland) with a nozzle 
atomizer, and nozzle orifice diameter of 0.7 mm. The SD was performed at a feed rate 10%, an 
atomizing air flow of 400 L/h, aspirator capacity of 100% and an inlet temperature of 100°C 
(outlet temperature approximately 45–47°C). The dry particles (PGA-co-PDL/L-leu NCMPs) 
were separated from the air stream using a high-performance cyclone (Büchi Labortechnik), and 
the dry particles were collected and stored in desiccator until further use. 
 
Nanocomposite Microparticles Characterization 
Yield 
The dry  powder  yield  was  determined  as  the  difference in the weight of the sample vial before 
and after product collection. The weight difference was compared to the initial total dry mass 
and the yield in  % (w/w) was calculated (n =3). 
 
Particle Size and Morphology 
To confirm the recovery of NPs from NCMPs with an appro- priate size range for cellular uptake, particle 
size and PDI of NPs following re-dispersion of blank and loaded NCMPs in water were measured. The 
measurements were recorded as mentioned in “Nanoparticle Characterization” Section, where 5 
mg of NCMPs were dispersed in 2 ml of deionized water then loaded into a cuvette and the 
measurements were recorded at 25°C (n=3). 
 
Spray dried PGA-co-PDL/L-Leu  NCMPs samples were mounted on aluminium stubs (pin stubs, 
13 mm) layered with a sticky conductive carbon  tab  and  coated with palladium (10–15 nm) using 
 
 
 
a sputter coater (EmiTech  K  550X  Gold  Sputter  Coater,  25  mA  for 3 min). The particles were 
then visualized using scanning electron microscopy (FEI Quanta™ 200 ESEM, Holland). 
 
 
Confocal Laser Scanning Microscopy 
FITC-BSA-loaded NR NPs spray-dried into NCMPs were observed under confocal microscope to 
visualise the adsorption of BSA onto the NPs. Briefly, a Zeiss 510 Meta laser scanning microscope 
mounted on a Axiovert 200 M BP computer-controlled inverted microscope was used to obtain the 
confocal images. A few milligrams of spray-dried NCMPs were placed in a single well of 8-well 
chambered (Fisher Scientific, UK) and imaged by excitation at a wavelength of 488 nm (green channel 
for FITC-BSA), 543 nm (red channel for Nile Red NPs) and a Plan Neofluar 63×/0.30 numerical 
aperture (NA) objective lens. Image analysis was carried out using the Zeiss LSM software. 
 
 
Protein Quantification by HPLC 
An HPLC method was developed to quantify the amount of BSA present in NCMPs. The 
chromatographic conditions were as follows: HPLC system Agilent 1100 series (Santa Clara, CA, USA) 
equipped with a column (Aeris 3.6 μm C4 200A Wide Pore 4.6 mm i.d. × 150 mm length), security 
cartridge of the same material (Phenomenex, UK) and soft- ware for data processing; mobile phase was 
composed of (A) 0.1% TFA in water and (B) 0.1% TFA in acetonitrile with a gradient flow of A/B from 
80:20 to 35:65 in 25 min, post-time 6 min; flow rate of 0.8 ml/min; injection volume of 100 μl; run 
temperature 40°C; UV detection at 214 nm and BSA retention time of 14.4 min. BSA calibration curve 
was prepared by accurate dilution of a previously prepared stock solution (1 mg/ml) in HPLC water and 
PBS (pH 7.4) to obtain the following concentrations: 0.5, 1, 2.5, 5, 10, 25, 50, 100 and 200 μg/ml of BSA 
(n=9, R2 =0.999). All solutions used in the process were filtered using 0.45 μm filters prior to use. Limit 
of Detection (LOD) in water—1.98 μg/ml, PBS—1.48 μg/ml and Limit of Quantification (LOQ) in 
water—3.24 μg/ml, PBS—3.20 μg/ml. 
 
 
In Vitro Release Studies 
BSA adsorbed PGA-co-PDL/L-leu NCMPs (20 mg) were transferred into Eppendorf’s and dispersed in 
2 ml of PBS, pH 7.4. The samples were incubated at 37°C and left rotating for 48 h at 20 RPM on a 
HulaMixer™ Sample Mixer (Life Technologies, Invitrogen, UK). At pre-determined time intervals up 
to 48 h, the samples were centrifuged (accuSpin Micro 17, Fisher Scientific, UK) at 17,000 g for 30 min 
and 1 ml of the supernatant removed and replaced with fresh medium. The supernatant was analysed 
using the HPLC method as mentioned above. Each experiment was repeated in triplicate and the result 
was the mean value of three different samples (n=3). The percentage cumulative BSA released was 
calculated using Eq. 2: 
 
 
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The primary structure of BSA released from the NCMPs after SD was determined by SDS-PAGE. SDS-
PAGE was per- formed on CVS10D omniPAGE vertical gel electrophoresis system (Geneflow Limited, 
UK) with 9% stacking gel pre- pared using ProtoGel stacking buffer (Geneflow Limited, UK) 
containing 0.4% of SDS. Protein molecular weight markers in the range 10–220 KDa (Geneflow 
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Limited, UK) and BSA were used as control. The protein loading buffer blue (2X) (0.5 M Tris–HCl 
(pH 6.8), 4.4% (w/v) SDS, 20% (v/v) Glycerol, 2% (v/v) 2- mercaptoethanol and bromphenolblue in 
distilled/deionised water) was added to the samples in 1:1 (v/v) buffer-to-sample ratio. After loading the 
samples (25 μl sample per well), the gel was run for approximately 2.5 h at a voltage of 100 V with 
Tris-Glycine-SDS PAGE buffer (10X) (Geneflow Limited, UK) containing 0.25 M Tris base, 1.92 M 
glycine and 1% (w/v) SDS. The gel was stained with colloidal coomassie blue and then destained in 
distilled water overnight. An image of the gel was scanned on a gel scanner (GS-700 Imaging 
Densitometer, Bio-Rad) equipped with Quantity One software. 
 
 
Circular Dichroism (CD) 
The secondary structure of standard BSA (control), BSA supernatant (after 1 h adsorption followed 
by centrifugation) and BSA released from NPs after 48 h was determined by measuring circular 
dichroism spectra. All CD experiments were performed using a J-815 spectropolarmeter (Jasco, UK) 
at 20°C as previously described (31). Five scans per sample using a 10 mm path-length cell were 
performed over a wavelength range 260 to 180 nm at a data pitch of 0.5 nm, band width of 1 nm and 
a scan speed 50 nm min−1. Far-UV CD spectra were collated for standard BSA, supernatant BSA 
in HPLC grade water, BSA released in PBS for 48 h. For all spectra, the baseline acquired in the 
absence of sample was subtracted (32). The secondary structure of the samples was estimated 
using the CDSSTR method (33) from the DichroWeb server (33–35). 
 
 
Activity 
The activity of BSA was investigated using 4-nitrophenyl acetate esterase substrate (NPA, Sigma 
Aldrich, UK) as described by Abbate et al. (36). Briefly, 1.2 ml of released BSA sample (50 μg/ml) 
in PBS was added to freshly prepared NPA solution (15 μl of a 5 mM solution in ACN) and 
incubated for 1 h using HulaMixer™ Sample Mixer. Thereafter, the solution was transferred to a 
plastic cuvette and absorbance measured at 405 nm. For positive control, standard BSA (50 μg/ml) 
was treated exactly the same as released sample whereas for negative control, PBS buffer alone 
was treated as sample. The relative residual esterolytic activity of the samples was calculated as 
the ratio of absorbance between the released BSA/standard BSA, with the esterolytic activity 
obtained for standard BSA considered to be 100%. 
 
In Vitro Aerosolization Studies 
The Next Generation Impactor (NGI) was employed to assess the aerosol performance of spray-dried 
NCMPs. The BSA adsorbed NCMPs were weighed (4 capsules each corresponding to 12.5 mg spray-
dried, powder equivalent to 5 mg of NPs) and manually loaded into the hydroxypropyl methylcellulose, 
HPMC, capsule (size 3), and placed in a Cyclohaler® (Teva pharma). The samples were drawn through 
the induction port into the NGI using a pump (Copley Scientific, Nottingham, UK) operated at a flow 
rate of 60 L/min for 4 s. The plates were coated with 1% tween 80: acetone solution and samples 
collected using a known volume of distilled water, and left on a roller-shaker for 48 h for the BSA to 
be released from NCMPs. The samples were centrifuged using an ultracentrifuge (as mentioned in 
“Preparation of Nanoparticles” Section) and the supernatants analysed using HPLC method as 
mentioned above to determine the amount of BSA deposited. The Fine Particle Fraction (FPF, %) was 
determined as the fraction of emitted dose deposited in the NGI with dae<4.46 μm, the mass median 
 
 
 
aerodynamic diameter (MMAD) was calculated from log-probability analysis, and the fine particle dose 
(FPD) was expressed as the mass of drug deposited in the NGI with dae<4.46 μm (n=3). 
 
Cell Viability Study 
The in vitro cytotoxicity of the empty PGA-co-PDL/L- leu NCMPs was evaluated using the MTT 
assay. The adenocarcinomic  human  alveolar  basal  epithelial   cell line, A549 (passage no. 32) or 
16HBE14o- cells (passage no. 32) were seeded in 100 μl (2.5 × 105 cells/ml) of RPMI-1640  medium  
supplemented  with  10%  foetal  calf serum/1% Antibiotic/Antimycotic solution (complete medium) 
in  96-well  plates  and  placed  in  an  incubator at  37°C  for  24  h  supplemented  with  5%  CO2.  
Then, 100  μl  of  freshly  prepared  NCMP  dispersions  in  complete medium were added to the wells 
to an appropriate concentration (0–2.5 mg/ml) (n = 3), and 10% dimethyl sulfoxide (DMSO) as a 
positive control. The formulations were assayed for toxicity over 24 h of incubation, followed by 
the addition of 40 μl of  a  5 mg/ml MTT solution in PBS to each well. After 2 h of incubation at 
37°C, the culture medium was gently removed and replaced by 100 μl of dimethyl sulfoxide in 
order to dissolve the formazan crystals. The absorbance of the solubilised dye, which correlates with 
the number of living cells, was measured at 570 nm using a plate reader (Molecular Devices, 
SpectraMAX 190). The percentage of viable cells in each well was calculated as the absorbance ratio 
between nanoparticle-treated and untreated control cells. 
 
 
Statistical Analysis 
All statistical analysis was performed using Minitab® 16 Statistical Software. One-way analysis of 
variance (ANOVA) using Minitab® 16 Statistical Software with the Tukey’s comparison was employed 
for comparing the formulations with each other. Statistically significant differences were assumed when 
p<0.05. All values are expressed as their mean ± standard deviation. 
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RESULTS 
 
Polymer Synthesis 
 
The synthesized PGA-co-PDL co-polymer (monomer ratio, 1:1:1) was a white powder with a molecular 
weight of 14.7,24.0 KDa for 6 h, 24 h as determined by the GPC. The integration pattern of the co-
polymer was confirmed by 1H- NMR spectra, (δH CDCl3, 300 MHz): 1.34 (s, 22 H, H-g), 1.65 (m, 8 H, 
H-e, e′, h), 2.32 (m, 6 H, H-d, d′, i), 4.05 (q)-4.18 (m) (6 H, H-a, b, c, f), 5.2 (s, H, H-j). 
 
Taguchi Design of Experiment (DoE) 
The Taguchi design was applied in this study to identify the 
significant factors that would influence the size of PGA-co- PDL NPs. Considering seven factors (1 factor 
at 2 levels and 6 factors at 3 levels) to be investigated, non-usage of an experimental design would have 
resulted in 2*36 =1,458 individual experiments which would be an arduous task and inefficient. 
 
The Taguchi L18  orthogonal array design resulted in 18 runs to be performed to yield the optimum 
conditions for each factor in achieving the smallest PGA-co-PDL NP size. Table II illustrates the structure 
of the L18 orthogonal array, the corresponding results and S/N ratios. The results obtained from 18 runs 
indicated particle sizes ranging from 138.7±6.4 nm (run 3) to 459.4±69.5 nm (run 11). Figure 1 shows 
the mean S/N graph of the particle size for each parameter level. The parameter with the largest range 
and corresponding rank (indicates the relative importance compared to other parameters) was considered 
as the critical factor affecting that particle size. 
 
Analysis of the particle sizes of 18 runs using the Taguchi’s ‘smaller-is-better’ criterion in Minitab® 16 
Statistical Software, the optimum conditions inferred from the range, rank and the S/N response graph 
were A1B3C3D3E2F2G2. The optimum formulation made using these conditions yielded NPs with a 
size of 128.50±6.57 nm lower than the minimum size of 138.7±6.4 nm obtained using run 3, PDI of 0.07± 
0.03 and zeta-potential of −10.2±3.75 mV. 
 
 
 
 
Fig. 1 Mean S/N graph for particle size response. Letters (A–E) denote the experimental parameters and numeric values denote 
the parameter levels (white diamond indicates maximum S/N value) (Mean±SD, n=6); Note: A—MW of Polymer, B—Org 
Sol (DCM), C—Aq. Vol (PVA), D—1st Aq. conc (PVA), E— Sonication time, F—Stirrer Speed and G—2nd Aq. conc 
(PVA). 
 
 
 
 
 
Table II Structure of Taguchi’s L18 Orthogonal Array, Corresponding Particle Size and S/N Ratios (Mean±SD, n=6) 
 
Runs Parameters       Particle Size (nm) PDI S/N Ratio (dB) 
 A B C D E F G    
Run 1 1 1 1 1 1 1 1 315.5±6.90 0.151±0.05 −49.979 
Run 2 1 1 2 2 2 2 2 186.5±4.30 0.097±0.03 −45.412 
Run 3 1 1 3 3 3 3 3 138.7±6.40 0.093±0.01 −42.843 
Run 4 1 2 1 1 2 2 3 210.1±18.7 0.116±0.04 −46.449 
Run 5 1 2 2 2 3 3 1 208.7±49.9 0.123±0.06 −46.389 
Run 6 1 2 3 3 1 1 2 182.0±3.20 0.075±0.04 −45.199 
Run 7 1 3 1 2 1 3 2 192.9±9.30 0.077±0.04 −45.705 
Run 8 1 3 2 3 2 1 3 149.3±2.50 0.075±0.01 −43.481 
Run 9 1 3 3 1 3 2 1 192.9±23.0 0.050±0.03 −45.704 
Run 10 2 1 1 3 3 2 2 269.1±68.9 0.205±0.04 −48.598 
Run 11 2 1 2 1 1 3 3 459.4±69.5 0.233±0.02 −53.243 
Run 12 2 1 3 2 2 1 1 242.5±19.1 0.188±0.06 −47.694 
Run 13 2 2 1 2 3 1 3 253.2±47.3 0.155±0.10 −48.069 
Run 14 2 2 2 3 1 2 1 217.3±18.9 0.116±0.01 −46.742 
Run 15 2 2 3 1 2 3 2 240.5±35.1 0.133±0.05 −47.622 
Run 16 2 3 1 3 2 3 1 169.3±7.60 0.144±0.04 −44.573 
Run 17 2 3 2 1 3 1 2 235.9±29.6 0.119±0.08 −47.453 
Run 18 2 3 3 2 1 2 3 221.7±11.0 0.150±0.04 −46.915 
A—MW of Polymer, B—Org Sol (DCM), C—Aq. Vol (PVA), D—1st Aq. conc (PVA), E—Sonication time, F—Stirrer Speed and G—2nd Aq. conc (PVA) 
 
 
Protein Adsorption 
Figure 2a shows the amount of BSA adsorbed per mg of NPs for different concentrations of BSA loaded. 
The average ad- sorption of BSA, μg per mg of NPs, increased significantly from 100: 4 (NP: BSA) 
loading concentration (4.75±0.39), 100:  10 (6.59 ± 1.28) to 100:  20 (10.23 ± 1.87) (p <0.05, 
ANOVA/Tukey’s comparison). Figure 2b shows the amount of BSA adsorbed in μg per mg of NPs at 
different time points for 100: 20 (NP: BSA) loading concentration. The average adsorption increased 
significantly from 30  min  (1.84 ± 0.82)  to  1  h  (10.23 ± 1.87) (p < 0.05, ANOVA/Tukey’s comparison) 
with no significant difference beyond 1 h compared to  that  of  2  h (8.76 ± 0.34)  and  24  h  (8.95 ± 
0.39)  (p > 0.05,  ANOVA/Tukey’s comparison) indicating maximum adsorption at 1 h. Table III lists 
the particle size and PDI of PGA-co-PDL NPs with and without BSA adsorption. As seen, there is a 
significant increase (p<0.05, ANOVA/Tukey’s comparison) in size which is attributed to the adsorption 
of BSA onto NPs as confirmed using confocal microscopy (“Confocal Laser Scanning Microscopy” 
Section). 
 
Fig. 2 Amount of BSA adsorbed per mg of NPs at different (a) BSA loading concentrations (NP: BSA) and (b) time points for 100: 20 (NP: BSA) BSA loading 
concentration, * is p<0.05, ANOVA/Tukey’s comparison (Mean±SD, n=3). 
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Table III Particle Size and PDI of PGA-co-PDL Nanoparticles Without and with BSA Adsorption 
 
* p<0.05, ANOVA/Tukey’s comparison 
a NPs characterised immediately after preparation without centrifugation, b NPs characterised after 
centrifugation but without adsorption of BSA, c NPs characterised after centrifugation and BSA 
adsorption.  
 
Nanocomposite Microparticles Characterization 
 
Yield 
 
A reasonable yield of SD, 40.36±1.80% for the empty PGA- co-PDL NCMPs and 42.35±3.17% for the 
BSA adsorbed PGA-co-PDL/L-leu NCMPs was obtained. 
 
Particle Size and Morphology 
The size of NPs after recovery from spray-dried blank NCMPs in water was 210.03±15.57 nm and PDI 
0.355±0.067 and for that of BSA loaded NCMPs was 282.46±2.17 nm and PDI 0.36±0.008, which is in 
the range of 200 to 500 nm for uptake by dendritic cells (DCs) (16–18). The shape and surface texture 
of NCMPs were investigated using scanning electron microscopy (Fig. 3). Photomicrographs of 
NCMPs showed irregular and corrugated microparticles. 
 
Fig. 3 SEM pictures of PGA-co-PDL/L-Leu Nanocomposite Microparticles (a) 5 μm and (b)2 μm. 
 
Confocal Laser Scanning Microscopy 
CLSM was used to observe the interaction of BSA with NPs. The  microscopic  images  in  Fig.  4a  
(split  view)  and  4b (orthogonal view) shows the spray-dried NCMPs containing the fluorescent NPs 
(red, labelled using NR dye) adsorbed with FITC-BSA (green). The image shows that FITC-BSA was 
evidently only present where the NPs were present, indicating their association. Moreover, the increase 
in size observed after adsorption also confirms the adsorption of BSA onto PGA-co-PDL NPs (Table 
 
 
 
III). 
 
Fig. 4 Confocal microscopic image of spray-dried microparticles containing the fluorescent nanoparticles 
(red, labelled using nile red dye) adsorbed with FITC-BSA (green) (a) Split view and (b) Orthogonal 
view. 
 
In Vitro Release Studies 
In vitro release studies were performed on NCMPs and reported as cumulative percentage BSA 
released over time (Fig. 5). An initial burst release of 30.15±2.33% (BSA) was observed followed by 
continuous release up to 5 h, with BSA release of 86.07±0.95%. After this time period, a slow 
continuous release of BSA was observed with release of 95.15±1.08% over 48 h, indicating an 
excellent release profile for the PGA-co- PDL/L-leu NCMPs. 
 
 
Fig. 5 In vitro release profiles for BSA adsorbed PGA-co-PDL/L-leu NCMPs in phosphate buffer 
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saline, pH 7.4 (Mean±SD, n=3). 
 
Protein Stability (SDS-PAGE and CD) and Activity 
The primary structure of BSA released from the NCMPs was investigated using SDS-PAGE analysis. 
Figure 6 reveals identical bands for the standard BSA and desorbed BSA from NCMPs without any 
newly noticeable bands of high and low molecular BSA. 
 
Fig. 6 SDS-PAGE of Lane 1: molecular weight standards, broad range (Bio-Rad Laboratories, Hercules 
CA, USA), Lane 2, 3: BSA standards, Lane 4, 5, 6: Desorbed BSA from PGA-co-PDL/L-leu NCMPs 
after 24 h. 
 
The secondary structure analysis was performed using CD spectral data. Figure 7a and b shows the 
structure of standard BSA, BSA supernatant and BSA released. In Fig 7a, the CD spectra show minima 
at 221–222 and 209–210 nm and maximum at about 195 nm for both samples, which is characteriistic 
of α-helical structure. Further structural analysis showed that the predominant structure of the protein 
was helical displaying 51 and 62.5% helicity respectively (Table IV). Moreover, the experimental data 
obtained for the standard BSA are in good agreement with previous reports (37). Figure 7b shows that 
BSA released displayed double minima at 208 and 222 nm and further spectra analysis indicated this 
sample adopted a reduced level helical conformation (circa 36% helical) (Table IV). Comparing the 
CD results of BSA released with that of standard BSA, the content of α-helix decreases by 15%, the 
β-sheet content increases by 8.9%, the turns content increases by 1%, and the random coils’ content 
increases by 3%, respectively. 
The residual esterolytic activity of the released BSA sample was calculated to be 77.73±3.19% 
relative to standard BSA. 
 
 
 
 
Fig. 7 CD spectra of (a) standard BSA (grey) and supernatant BSA (black) and (b) standard BSA (grey) 
and BSA released (black). 
 
Table IV The Percentages of the Secondary Structures of Standard, Supernatant and Released BSA 
Samples 
 
 
The content and level of secondary structure elements in the peptide was calculated from spectral data 
using the DichroWeb server software as described in “Materials and Methods” Section. 
 
 
In Vitro Aerosolization Studies 
The deposition data obtained from spray-dried formulations displayed a FPD of 112.87±33.64 μg, FPF 
of 76.95±5.61% and MMAD of 1.21±0.67 μm. This suggest that the BSA adsorbed PGA-co-PDL/L-leu 
NCMPs were capable of delivering efficient BSA to the lungs, and are expected to deposit the majority 
of the emitted dose to the bronchial-alveolar region of the lungs (3). 
 
Cell Viability Study 
The  non-adsorbed  PGA-co-PDL  NCMPs  appear  to  be well tolerated by both the cell lines, with a cell 
viability of 87.01 ± 14.11% (A549 cell line) and 106.04 ± 21.14% (16HBE14o- cell line) (Fig. 8) at 1.25 
mg/ml concentration after 24 h exposure indicating a good toxicity profile without any significant 
difference in cell viability between particle loadings. This provides an indication about the feasibility of 
using PGA-co-PDL polymers as safe carriers for pulmonary drug delivery. 
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Fig. 8 A549 & 16HBE14o- cell viability measured by MTT assay after 24 h exposure to PGA-co-PDL 
NCMPs (Mean±SD, n=3). 
 
 
DISCUSSION 
 
Nanoparticle Preparation and Characterization 
The PGA-co-PDL NPs were prepared using a modified oil-in water(o/w) single emulsion solvent 
evaporation method (29). The results of 18 runs, suggested by Taguchi’s L18 orthogonal array, resulted 
in NPs of size<150 nm. However, this increases to about 200–300 nm after centrifugation and BSA 
adsorption. This according to the literature suggests an effective uptake by DCs (15–17). The effects of 
each factor are discussed in detail below: 
 
Factor D, PVA concentration (range=3.17, rank=1), is the most important factor affecting the particle 
size. The S/N ratios at three levels indicated that particle size almost linearly decreased with increase in 
surfactant concentration from 2.5 to 10%w/v (S/N ratio, r2 =0.997). The particle size decreases because at 
lower concentrations there is inadequate amount of surfactant to cover all the surfaces of PGA-co-PDL NPs 
(38). The uncovered NPs then tend to aggregate until a point where there is adequate amount of 
surfactant to cover the total surface area of the aggregated NPs, and form a stable system leading to 
larger particles. However, with an increase in surfactant concentration it was possible to efficiently cover 
all the surfaces of NPs thereby stabilizing the system avoiding aggregation and resulting in smaller PGA-
co-PDL NPs (38). This effect of decrease in particle size with an increase in surfactant concentration, 
PVA, was also observed by Mitra and Lin (39). 
 
The S/N ratios of factor A, molecular weight of the polymer (range=2.19, rank=3), at two levels, 
suggested a directly proportional relationship with MW of polymer, i.e. the particle size decreases with a 
decrease in the MW of the polymer. This can also be evident from the lower particle size measurements 
observed using 14.7 KDa MW polymer (runs 1–9) relative to 24 KDa MW polymer (runs 10–18). 
As the MW of polymer increases, the viscosity of the polymeric solution also increases, thereby 
imposing difficulty in breaking them into smaller emulsion droplets when compared to lower MW 
polymer requiring lower efficiency to breakdown under similar conditions. This increase in size of the 
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particles has also been observed by others and is reported to be associated with high MW polymers 
(5,40,41). 
 
The S/N ratios of factor B, volume of organic solvent (DCM, range=2.32, rank=2), at three levels 
indicated that particle size almost linearly decreased with increase in volume from 1 to 2 ml (S/N ratio, 
r2 =0.999). This decrease in particle size is attributed to the decrease in viscosities of the polymer solution 
(keeping the amount and MW of polymer constant). This makes it easier to break into smaller emulsion 
droplets resulting in a decreased particle size as explained above. This effect could also be observed with 
factor C, volume of 1st aqueous phase (range=1.23, rank=5), where a decrease in volume increased the 
viscosity thereby resulting in an increase in particle size. 
 
The S/N ratios for factor E, sonication time (range=2.09, rank=4), did not follow any particular trend; 
however, the 2nd level was found to be the optimum for achieving smaller particle size. The S/N ratios 
for parameters F, stirrer speed (the speed at which the magnetic bar was rotating for evaporation of 
DCM in the external phase) and G, 2nd PVA concentration have a low range of 0.34 and 0.18 
respectively indicating that they have a minimal influence over the size of NPs produced. Therefore, the 
optimum conditions inferred result in NPs of size suitable for cellular uptake into DC as established in 
the literature (15–17,42,43). 
 
The adsorption of BSA onto NPs is expected to be mainly driven by hydrophobic, electrostatic (ionic) 
interactions and hydrogen bonding (44). However, in this study as the NPs, evident from zeta-potential 
values, are negatively charged and BSA in water is also highly negatively charged (45) suggesting that 
the electrostatic interactions are minimal and that the adsorption process is dominated by the 
hydrophobic interactions and hydrogen bonding. The BSA adsorption onto NPs increased with an increase 
in NP: BSA ratio from 100: 4 to 100: 20, which was expected as the amount of BSA available for 
adsorption increased. Figure 2b suggests that the surface of NPs was saturated with BSA after 1 h suggesting 
maximum adsorption with 100: 20 (NP: BSA) BSA loading concentration. 
 
 
Nanocomposite Microparticles Characterization 
NCMPs were produced by SD using L-leu as a carrier and a dispersibility enhancer. The SEM pictures 
(Fig. 3) show irregular or wrinkled surface which is due to an excessive build-up of vapour pressure 
during water evaporation in the SD pro- cess and occurs with hydrophobic amino acids, such as L-Leu 
(8,46,47). 
The release profile shows more than 90% of the BSA released within 48 h this is because of weaker 
hydrophobic interactions between BSA and NPs compared to the strong ionic interactions. Moreover, the 
identical bands observed for BSA standard and desorbed BSA from NCMPs suggests that protein has 
maintained its primary structure and was neither degraded nor affect- ed by the adsorption and SD 
procedure. 
The secondary structure of BSA in the formulation was analysed using CD spectroscopy, a 
valuable technique in analysing the protein structure (31). The BSA released samples confirms the 
presence of α-helix and β-sheets though decreased compared to standard BSA. However, in protein 
secondary structure, it is believed that the β-sheet structure is sometimes observed as a special α-helix 
only with two amino acid residues through stretching resulting from the breakage of hydrogen bond 
(37,48). 
It is established that BSA possesses an enzyme-like activity with the ability to hydrolyse substrates 
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such as p-nitophenyl esters (36,49,50). In this study, the released BSA sample retained approximately 
77% of relative residual esterolytic activity com- pared to standard BSA. A reduction in BSA activity to 
60% was also observed by Abbate et al. when released from biohybrid hydrogels (36). The adsorption 
and desorption process of BSA could have influenced the structure (evident from a decreased helicity 
determined by CD) and thus the activity. However, the retention of 77% ester hydrolysis activity would 
encourage the exploration of the delivery system for further usage. 
The FPF value suggests an excellent aerosolization performance and deep lung deposition profile. The 
surface activity of the relatively strong hydrophobic alkyl side chain of L-leu accumulating at the particle 
surface during SD reduces the surface free energy of the dry powder and cohesive inter-particulate 
interactions and this might be a plausible explanation for the enhanced dispersibility (8,23). In addition, 
the dispersibility enhancing property of L-leu resulting from its corrugated surface that reduces the 
contact points between particles leads to an improved aerosolization characteristic of powders (22,47,51). 
Similar reports have also demonstrated the enhanced aerosol performance with L-leu containing 
formulations (22,47,51,52). Moreover, the MMAD values show an efficient delivery of NCMPs 
containing BSA to the deep lungs mainly to the bronchial-alveolar region (3). A study by Todoroff et al. 
have shown that more intense specific immune responses could be achieved by targeting the antigen to 
the deep lungs than to the upper airways (53). Also, Menzel et al. have shown that upon inhalation of 
Pneumovax®, a pneumococcal polysaccharide vaccine, by healthy volunteers the vaccine deposited in 
the alveolar region displayed increased serum antibody levels compared to that deposited in the larger 
airways (54). Thus, this deposition to the deep lungs may generate stronger immune responses. 
The NGI data suggests a deposition mainly in the bronchial-alveolar region of the lungs (3), 
thus the cell viability studies were performed on A549 cell line (adenocarcinomic human alveolar basal 
epithelial cells) and 16HBE14o- cell line (human bronchial epithelial cells). The results show that both 
the cell lines were tolerant to the NCMPs up to 1.25 mg/ml concentration encouraging further 
investigation in animals. 
 
 
 
CONCLUSIONS 
PGA-co-PDL NPs of appropriate size to target DCs were successfully produced using Taguchi L18 
orthogonal array DoE. BSA adsorption onto NPs in the ratio of 100: 20 (NP: BSA) for 1 h at room 
temperature produced the maximum adsorption of BSA (10.23 ± 1.87 μg of protein per mg of NPs). The 
BSA adsorbed NPs were successfully spray-dried using L-leu into NCMPs producing a yield of ± 3.17% 
and the NCMPs had irregular and  corrugated morphology. The BSA released from the NCMPs was 
shown to be maintaining its structure under SDS- PAGE and CD analysis with 77% of relative residual 
esterolytic activity. Moreover, FPF of 76.49 ± 6.26% and MMAD of 1.21 ± 0.67 μm values indicate deep 
lung de- position with NCMPs showing a low toxicity profile. This study suggests that PGA-co-PDL 
NCMPs could be used as a novel carrier for pulmonary vaccine delivery. 
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